Skip to main content

Advertisement

SpringerLink
Log in

GIST Treatment Options after Tyrosine Kinase Inhibitors

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

The management of advanced gastrointestinal stromal tumor (GIST) has been dramatically altered by the development of tyrosine kinase inhibitors. The disease, which had a median overall survival of 12 months for patients with unresectable disease, now has a median survival approaching 5 or more years. The challenge faced clinically is how to care for patients when they have progressed on all approved therapies. Clinical trials evaluating the role of novel combination therapies with investigational agents that target AKT/PI3K pathways are of interest especially given the preclinical rationale available. The addition of an mTOR inhibitor can be tried as these are available, but requires care and monitoring for additional toxicities. With improved understanding of this disease, which we thought of as one biology, personalized therapies are being studied and tested and is particularly relevant for GIST that are less responsive to the standard kinase inhibitors, such as platelet-derived growth factor alpha (PDGFRA) D842V and wild-type/succinate dehydrogenase (SDH)-deficient GIST. IGF1R inhibitors as a class are not being developed because of the lack of significant efficacy in many clinical trials and the efficacy in WT GIST has been limited; to date drugs targeting VEGFR, such as sunitinib and regorafenib, appear to be the best agents available for this group of patients. The exciting findings seen with CTLA4 and PD-1/PD-L1 antibodies in melanoma and other solid tumors is exciting, especially because there is a growing body of evidence that such approaches have biologic rationale; clinical trials evaluating these agents are awaited with interest. Last, recent work has shed light on older agents that may have a role in GIST. Moving forward to test these agents alone or in combination with TKIs offers potentially new strategies for treating advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61(22):8118–21.

    CAS  PubMed  Google Scholar 

  2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.

    Article  CAS  PubMed  Google Scholar 

  3. Corless CL. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib. J Clin Oncol. 2005;23(23):5357–64.

    Article  CAS  PubMed  Google Scholar 

  4. Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769–76.

    Article  CAS  PubMed  Google Scholar 

  5. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108(1):314–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358(9291):1421–3.

    Article  PubMed  Google Scholar 

  8. Blanke CD, Demetri GD, von Mehren M, et al. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol. 2008;26(4):620–5.

    Article  CAS  PubMed  Google Scholar 

  9. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.

    Article  CAS  PubMed  Google Scholar 

  11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J Med. 2002;347(7):472–80.

    Article  CAS  PubMed  Google Scholar 

  12. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.

    Article  CAS  PubMed  Google Scholar 

  13. Blanke CD, Rankin C, Demetri GD, et al. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. J Clin Oncol. 2008;26(4):626–32.

    Article  CAS  PubMed  Google Scholar 

  14. Antonescu CR. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clin Cancer Res. 2005;11(11):4182–90.

    Article  CAS  PubMed  Google Scholar 

  15. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743–9.

    Article  CAS  PubMed  Google Scholar 

  16. Heinrich MC, Corless CL, Blanke CD. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncoly. 2006;24(29):4764–74.

    Article  CAS  Google Scholar 

  17. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 Pt 1):5398–405.

    Article  CAS  PubMed  Google Scholar 

  18. Wang C-M, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2010;136(7):1065–71.

    Article  CAS  PubMed  Google Scholar 

  19. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008;105(24):8387–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013;15(4):386–95.

    Article  CAS  PubMed  Google Scholar 

  21. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865–78.

    CAS  PubMed  Google Scholar 

  22. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247–53.

    Article  Google Scholar 

  23. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  CAS  PubMed  Google Scholar 

  24. Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.

    Article  CAS  PubMed  Google Scholar 

  25. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Reichardt P, Montemurro M, Gelderblom H. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10564.

    Google Scholar 

  27. Kindler HL, Campbell NP, Wroblewski K. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium Trial. Journal of Clinical Oncology (ASCO Meeting Abstracts) 2011;29(Suppl 15):10009.

  28. Heinrich MC, Carden R, Griffith D. In vitro activity of sorafenib against imatinib-and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10500.

    Google Scholar 

  29. Reichardt P, Blay J, Gelderblom H. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15.

  30. Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011;104(11):1686–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J of Cancer. 2013;109(9):2309–15.

    Article  CAS  Google Scholar 

  32. Trent JC, Wathen K, Mehrenvon M. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):10006.

    Google Scholar 

  33. Gardner K, Judson I, Leahy M, Barquin E. Gardner: 9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS]). Eur J Cancer Suppl. 2009;7(2):591–1.

  34. Blay J, Le Cesne A, Bin-Bui N, Bouché O, Adenis A. Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. J Clin Oncol (ASCO Meeting Abstracts). 2011;29 Suppl 4:85.

    Google Scholar 

  35. Le Cesne A, Blay J-Y, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010;46(8):1344–51.

    Article  PubMed  Google Scholar 

  36. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(16):4375–84. This paper reports on preclinical data testing crenolanib, a PDGFRA inhibitor, which is the first agent to demonstrate significant inhibition of the PDGFRA D842V mutation.

    Article  CAS  PubMed  Google Scholar 

  37. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Sápi Z, Füle T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol. 2011;20(1):22–33.

    Article  PubMed  Google Scholar 

  39. Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 2011;31(9):3019–25.

    PubMed  Google Scholar 

  40. Schöffski P, Reichardt P, Blay J-Y, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21(10):1990–8.

    Article  PubMed  Google Scholar 

  41. Hohenberger P, Bauer S, Gruenwald V. Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. J Clin (ASCO Meeting Abstracts). 2010;28 Suppl 15:10048.

    Google Scholar 

  42. Richter S, Pink D, Hohenberger P. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15:10038.

    Google Scholar 

  43. Palassini E, Fumagalli E, Coco P. Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2008;28 Suppl 15:21515.

    Google Scholar 

  44. Piovesan C, Fumagalli E, Coco P. Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10565.

    Google Scholar 

  45. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007;26(54):7560–8.

    Article  CAS  PubMed  Google Scholar 

  46. Li F, Growney J, Battalagine L. The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines. 102nd Annual Meeting of the AACR Chicago 2012; Abstract 2239.

  47. Floris G, Sciot R, Wozniak A. Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. J Clin Onco (ASCO Meeting Abstracts). 2010;28 Suppl 15:10020.

    Google Scholar 

  48. Van Looy T, Wozniak A, Sciot R. Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models. J Clin Oncol (ASCO Meeting Abstracts). 2012;30(Suppl)):10030.

    Google Scholar 

  49. Chiorean EG, Mahadevan D. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:2558.

    Google Scholar 

  50. Wagner AJ, Bendell JC, Dolly S. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):3020.

    Google Scholar 

  51. Conley AP, Araujo D, Ludwig J, Ravi V. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10563.

    Google Scholar 

  52. Bendell JC, Rodon J, Burris HA. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90.

    Article  CAS  PubMed  Google Scholar 

  53. Gonzalez-Angulo A, Juric D, Argiles G. Safety, pharmcokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first in-human study. J Clin Oncol (ASCO Meeting Abstracts). 2013;31(Suppl):2531.

    Google Scholar 

  54. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761–2.

    Article  CAS  PubMed  Google Scholar 

  55. Trepel J, Mollapour M, Giaccone G. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–49.

    Article  CAS  PubMed  Google Scholar 

  56. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 2004;103(3):1078–84.

    Article  CAS  PubMed  Google Scholar 

  57. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66(18):9153–61.

    Article  CAS  PubMed  Google Scholar 

  58. Lundgren K, Zhang H, Brekken J, Huser N. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8:921–9.

    Article  CAS  PubMed  Google Scholar 

  59. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007;13(6):1775–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Fletcher JA, Debiec-Rychter M, Swank S, Morgan J. HSP90 inhibitor STA-9090 potently suppresses secondary KIT kinase-domain mutations responsible for gastrointestinal stromal tumor (GIST) progression during imatinib therapy. Mol Cancer Ther. 2009;8 Suppl 1:B184.

    Article  Google Scholar 

  61. Floris G, Debiec-Rychter M, Wozniak A, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther. 2011;10(10):1897–908.

    Article  CAS  PubMed  Google Scholar 

  62. Floris G, Sciot R, Wozniak A, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res. 2011;17(17):5604–14.

    Article  CAS  PubMed  Google Scholar 

  63. Smyth T, Van Looy T, Curry JE, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther. 2012;11(8):1799–808.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Hsueh Y-S, Yen C-C, Shih N-Y, Chiang N-J, Li C-F, Chen L-T. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy. 2013;9(2):220–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Wagner AJ, Morgan JA, Chugh R, Rosen LS. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol (ASCO Meeting Abstracts). 2008;26 Suppl 15:10503.

    Google Scholar 

  66. Elfiky A, Saif MW, Beeram M, O'Brien S. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol (ASCO Meeting Abstracts). 2008;26 Suppl 15.

  67. Samuel TA, Sessa C, Britten C, Milligan KS. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15:2528.

    Google Scholar 

  68. Demetri GD, Le Cesne A, Mehren von M. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO Gastrointestinal Cancers Symposium 2010; abstract 64.

  69. Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013;19(21):6020–9.

    Article  CAS  PubMed  Google Scholar 

  70. Dickson MA, Okuno SH, Keohan ML, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24(1):252–7. Clinical trial utilizing a HSP-90 inhibitor demonstrating some stabilization of disease.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Demetri GD, Heinrich MC. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):10011.

    Google Scholar 

  72. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  73. Janeway KA, Liegl B, Harlow A, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007;67(19):9084–8.

    Article  CAS  PubMed  Google Scholar 

  74. Corless CL, Beadling C, Justusson E. Evaluation of the presence of IGF1R overexpression in wild-type and kinase mutant GI stromal tumors. J ClinOncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10506.

    Google Scholar 

  75. Lasota J, Wang Z, Kim SY, Helman L. Expression of the receptor for type 1 insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol. 2013;37(1):114–9. The largest pathology study of expression of IGF1R in GIST.

    Article  PubMed Central  PubMed  Google Scholar 

  76. Belinsky MG, Rink L, Flieder DB. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild type SDHB-negative gastrointestinal stromal tumors. Genes. 2013;52(2):214–24. Report of Wild type GIST evaluating IGF1R expression as well as mutations in SDH family members, reporting SDHA mutations which appear to be common in older patients with SDH-deficient GIST.

    CAS  Google Scholar 

  77. Day FL, Desai J, Corless CL, Heinrich MC, Zalcberg J. Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. Med Oncol. 2011;28 Suppl 1:S162–4.

    Article  PubMed  Google Scholar 

  78. Mahadevan D, Sutton GR, Arteta-Bulos R, et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014;73(3):467–73.

    Article  CAS  PubMed  Google Scholar 

  79. Borg C, Terme M, Taïeb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114(3):379–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Ménard C, Blay J-Y, Borg C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563–9. A study reporting the predictive value of IFN-gamma and NK cells in GIST; this group was one of the first to report the potential role of NK cells in GIST and in response to imatinib.

    Article  PubMed  Google Scholar 

  81. Cameron S, Haller F, Dudas J, et al. Immune cells in primary gastrointestinal stromal tumors. Eur J Gastroenterol Hepatol. 2008;20(4):327–34.

    Article  CAS  PubMed  Google Scholar 

  82. van Dongen M, Savage NDL, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899–909.

    PubMed  Google Scholar 

  83. Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3499–510.

  84. Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2012;17(9):1094–100. Preclinical study in a GIST mouse model demonstrating the importance of T cells in the antitumor response of imatinib.

    Google Scholar 

  85. Chen LL, Chen X, Choi H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother. 2012;61(7):1113–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2007;448(7154):645–6.

    Article  CAS  PubMed  Google Scholar 

  87. Boichuk S, Lee DJ, Mehalek KR, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 2014;74(4):1200–13. One of two papers recently reporting the results of drug repurposing studies.

    Article  CAS  PubMed  Google Scholar 

  88. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013;12(7):1299–309. Second paper reporting the results of drug repurposing studies.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Natthapol Songdej declares that he has no conflict of interest. Margaret von Mehren serves as a scientific adviser to Novartis, and has received funds for clinical research from Arog LLC, Novartis, Bayer, Astex, Infinity, and Synta, and has served as study PI for the Linsitinib trial (NCT01560260).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Natthapol Songdej MD & Margaret von Mehren MD

Authors
  1. Natthapol Songdej MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret von Mehren MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret von Mehren MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Songdej, N., von Mehren, M. GIST Treatment Options after Tyrosine Kinase Inhibitors. Curr. Treat. Options in Oncol. 15, 493–506 (2014). https://doi.org/10.1007/s11864-014-0295-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-014-0295-3

Keywords

Search

Navigation